Preclinical and phase I randomized study of a potent inhalable nanobody targeting TSLP for the treatment of airway inflammation. Zhu M, Ma L, Gai J, Li G, et al. J Allergy Clin Immunol 2025;156:1314-1327.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhu M, Ma L, Gai J, Li G, et al. Preclinical and phase I randomized study of a potent inhalable nanobody targeting TSLP for the treatment of airway inflammation. J Allergy Clin Immunol 2025;156:1314-1327.
PMID: 40602691